Drug Adherence and Treatment Duration for Denosumab and Mortality Risk Among Hip Fracture Patients

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2023 Jul 19

PMID 37466659

Authors

Yi-Lun Tsai

Chih-Hsing Wu

Chia-Chun Li

Chien-An Shih

Yin-Fan Chang

Jawl-Shan Hwang

Ta-Wei Tai

Affiliations

Soon will be listed here.

Abstract

Purpose: Prescription of anti-osteoporotic medications (AOMs) after osteoporotic hip fracture may increase bone mineral density (BMD) and decrease mortality risk. However, few studies have been conducted on drug adherence and treatment duration for denosumab, a popular choice among AOMs. This study aimed to assess the impact of denosumab adherence and treatment duration on the mortality risk of hip fracture patients after surgery.

Methods: We conducted a cohort study using nationwide population data from National Health Insurance Research Database (NHIRD) in Taiwan. Patients newly diagnosed with osteoporosis and hip fracture between 2008 and 2019 who used denosumab after surgery were included. We assessed drug adherence, treatment duration, and other parameters associated with patient outcomes.

Results: A total of 21,316 patients diagnosed with osteoporotic hip fractures were included. Compared with a > 7-month drug interval for denosumab, an interval of ≤ 7 months led to lower all-cause mortality risk (hazard ratio (HR): 0.60, 95% confidence interval (CI): 0.57 ~ 0.64). Patients with denosumab treatment for over 1, 2, and 3 years had lower all-cause mortality risk (HR&CI: 0.68 (0.64 ~ 0.73), 0.48 (0.43 ~ 0.53), 0.29 (0.26 ~ 0.33)) than those with treatment duration < 1 year. Analysis after excluding short-term death yielded similar results. Analysis of causes of death also showed that good adherence and longer duration were associated with reduced mortality due to cancer and cardiovascular disease.

Conclusion: Better drug adherence and longer duration of denosumab treatment are associated with lower all-cause mortality risk among hip fracture patients after surgery. Our study highlights the benefits of a proper time interval of denosumab administration. These findings provide important insight into management of osteoporotic hip fractures and may inform clinical practice and development of guidelines.

Citing Articles

Exploring mortality risk factors and specific causes of death within 30 days after hip fracture hospitalization.

Wu C, Tsai C, Hsu Y, Yang H Sci Rep. 2024; 14(1):27544.

PMID: 39528781 PMC: 11555071. DOI: 10.1038/s41598-024-79297-z.

Asia-Pacific consensus on long-term and sequential therapy for osteoporosis.

Tai T, Chen H, Shih C, Huang C, McCloskey E, Lee J Osteoporos Sarcopenia. 2024; 10(1):3-10.

PMID: 38690538 PMC: 11056428. DOI: 10.1016/j.afos.2024.02.001.

The Effects of Polyphenols on Bone Metabolism in Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Control Trials.

Salvio G, Ciarloni A, Gianfelice C, Lacche F, Sabatelli S, Giacchetti G Antioxidants (Basel). 2023; 12(10).

PMID: 37891909 PMC: 10604028. DOI: 10.3390/antiox12101830.

References

ONeill T, Roy D . How many people develop fractures with what outcome?. Best Pract Res Clin Rheumatol. 2005; 19(6):879-95. DOI: 10.1016/j.berh.2005.06.003. View

Sattui S, Saag K . Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol. 2014; 10(10):592-602. DOI: 10.1038/nrendo.2014.125. View

Tarazona-Santabalbina F, Belenguer-Varea A, Rovira-Daudi E, Salcedo-Mahiques E, Cuesta-Peredo D, Domenech-Pascual J . Early interdisciplinary hospital intervention for elderly patients with hip fractures : functional outcome and mortality. Clinics (Sao Paulo). 2012; 67(6):547-56. PMC: 3370304. DOI: 10.6061/clinics/2012(06)02. View

Yu S, Cheng J, Chen Y, Chen J, Hsu C, Lai H . Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study. BMC Geriatr. 2019; 19(1):290. PMC: 6819351. DOI: 10.1186/s12877-019-1278-9. View

Tai T, Li C, Huang C, Chan W, Wu C . Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study. Bone. 2021; 154:116216. DOI: 10.1016/j.bone.2021.116216. View

Reid I, Horne A, Mihov B, Stewart A, Garratt E, Wong S . Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018; 379(25):2407-2416. DOI: 10.1056/NEJMoa1808082. View

Cornelissen D, de Kunder S, Si L, Reginster J, Evers S, Boonen A . Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int. 2020; 31(9):1645-1669. PMC: 7423788. DOI: 10.1007/s00198-020-05378-0. View

Kendler D, Cosman F, Stad R, Ferrari S . Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2021; 39(1):58-74. PMC: 8799550. DOI: 10.1007/s12325-021-01936-y. View

Morizio P, Burkhart J, Ozawa S . Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Ann Pharmacother. 2018; 52(10):1031-1041. DOI: 10.1177/1060028018768808. View

10.

Anastasilakis A, Makras P, Yavropoulou M, Tabacco G, Naciu A, Palermo A . Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. J Clin Med. 2021; 10(1). PMC: 7796169. DOI: 10.3390/jcm10010152. View

11.

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen E, Guanabens N . Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017; 105:11-17. DOI: 10.1016/j.bone.2017.08.003. View

12.

Lyu H, Yoshida K, Zhao S, Wei J, Zeng C, Tedeschi S . Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. Ann Intern Med. 2020; 173(7):516-526. DOI: 10.7326/M20-0882. View

13.

Huang C, Shiao M, Mao T . Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic. Patient Prefer Adherence. 2021; 15:1579-1584. PMC: 8289459. DOI: 10.2147/PPA.S316144. View

14.

Chandran M, Hao Y, Kwee A, Cheen M, Chin Y, Ng V . Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia. Osteoporos Int. 2021; 33(1):251-261. PMC: 8379568. DOI: 10.1007/s00198-021-06085-0. View

15.

Boonen S, Adachi J, Man Z, Cummings S, Lippuner K, Torring O . Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011; 96(6):1727-36. DOI: 10.1210/jc.2010-2784. View

16.

Miedany Y, El Gaafary M, Toth M, Hegazi M, Aroussy N, Hassan W . Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?. Clin Rheumatol. 2021; 40(10):4225-4232. DOI: 10.1007/s10067-021-05757-w. View

17.

Phu S, Bani Hassan E, Vogrin S, Kirk B, Duque G . Effect of Denosumab on Falls, Muscle Strength, and Function in Community-Dwelling Older Adults. J Am Geriatr Soc. 2019; 67(12):2660-2661. DOI: 10.1111/jgs.16165. View

18.

Menendez-Colino R, Alarcon T, Gotor P, Queipo R, Ramirez-Martin R, Otero A . Baseline and pre-operative 1-year mortality risk factors in a cohort of 509 hip fracture patients consecutively admitted to a co-managed orthogeriatric unit (FONDA Cohort). Injury. 2018; 49(3):656-661. DOI: 10.1016/j.injury.2018.01.003. View

19.

Hsu T, Hsu C, Wang S, Huang C, Li L . Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients. J Clin Med. 2019; 8(7). PMC: 6678904. DOI: 10.3390/jcm8070932. View

20.

Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H . Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol. 2009; 175(2):473-8. PMC: 2716948. DOI: 10.2353/ajpath.2009.080957. View